用于逆转直接口服抗凝剂的andexanet alfa（Andexxa）。
Andexanet Alfa (Andexxa) for the Reversal of Direct Oral Anticoagulants.
作者信息
Momin Jayed H, Candidate PharmD, Hughes Gregory J
出版信息
P T. 2019 Sep;44(9):530-549.
Abstract
Andexanet alfa (Andexxa) for the reversal of direct oral anticoagulants.
摘要
用于逆转直接口服抗凝剂的andexanet alfa（Andexxa）。
相似文献
1
Andexanet Alfa (Andexxa) for the Reversal of Direct Oral Anticoagulants.
P T. 2019 Sep;44(9):530-549.
2
Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban.
J Pharm Technol. 2019 Jun;35(3):119-125. doi: 10.1177/8755122519839437. Epub 2019 Mar 28.
3
Andexanet Alfa (Andexxa) Formulary Review.
Crit Pathw Cardiol. 2019 Jun;18(2):66-71. doi: 10.1097/HPC.0000000000000177.
4
Andexanet Alfa: First Global Approval.
Drugs. 2018 Jul;78(10):1049-1055. doi: 10.1007/s40265-018-0940-4.
5
Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA.
Drugs Ther Perspect. 2018;34(11):507-512. doi: 10.1007/s40267-018-0561-8. Epub 2018 Oct 5.
6
Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Future Cardiol. 2019 Nov;15(6):395-404. doi: 10.2217/fca-2019-0038. Epub 2019 Oct 31.
7
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Am J Med. 2019 Jan;132(1):38-41. doi: 10.1016/j.amjmed.2018.06.028. Epub 2018 Jul 25.
8
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
Ann Pharmacother. 2019 Sep;53(9):940-946. doi: 10.1177/1060028019835209. Epub 2019 Feb 27.
9
Real-world utilization of andexanet alfa.
Am J Emerg Med. 2020 Apr;38(4):810-814. doi: 10.1016/j.ajem.2019.12.008. Epub 2019 Dec 10.
10
Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.
Pharmacotherapy. 2019 Aug;39(8):861-865. doi: 10.1002/phar.2306. Epub 2019 Jul 18.
引用本文的文献
1
Visualized Efficacy of Andexanet Alfa in an Elderly Trauma Patient with an Unstable Pelvic Fracture.
JMA J. 2024 Jul 16;7(3):438-440. doi: 10.31662/jmaj.2024-0007. Epub 2024 Jun 3.
2
Non-traumatic Spinal Subdural Hemorrhage Associated With Rivaroxaban Use.
Cureus. 2024 Apr 28;16(4):e59208. doi: 10.7759/cureus.59208. eCollection 2024 Apr.
3
Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding.
Nat Commun. 2024 May 9;15(1):3912. doi: 10.1038/s41467-024-48278-1.
4
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.
CNS Drugs. 2023 Jun;37(6):477-487. doi: 10.1007/s40263-023-01006-7. Epub 2023 May 3.
5
Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice.
Pharmacy (Basel). 2023 Feb 11;11(1):34. doi: 10.3390/pharmacy11010034.
6
Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists.
Glob Cardiol Sci Pract. 2022 Dec 30;2022(3):e202221. doi: 10.21542/gcsp.2022.21.
7
Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty.
Emerg Med Int. 2021 Nov 16;2021:2945978. doi: 10.1155/2021/2945978. eCollection 2021.
8
"Accessory After the Factors": A Rare Case of an Acquired Factor VIII Inhibitor in a 75-Year-Old Man on Rivaroxaban.
Cureus. 2021 Oct 8;13(10):e18597. doi: 10.7759/cureus.18597. eCollection 2021 Oct.
9
Institutional Experience of Using Andexanet Alfa.
Cureus. 2020 Jul 13;12(7):e9173. doi: 10.7759/cureus.9173.
本文引用的文献
1
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7.
2
Andexanet Alfa: First Global Approval.
Drugs. 2018 Jul;78(10):1049-1055. doi: 10.1007/s40265-018-0940-4.
3
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
Blood Adv. 2017 Sep 22;1(21):1827-1838. doi: 10.1182/bloodadvances.2017007112. eCollection 2017 Sep 26.
4
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085. Epub 2017 Dec 1.
5
Evaluation of bleeding in patients receiving direct oral anticoagulants.
Vasc Health Risk Manag. 2017 Aug 23;13:325-342. doi: 10.2147/VHRM.S121661. eCollection 2017.
6
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11.
7
National Trends in Ambulatory Oral Anticoagulant Use.
Am J Med. 2015 Dec;128(12):1300-5.e2. doi: 10.1016/j.amjmed.2015.05.044. Epub 2015 Jul 2.
8
The real decoy: an antidote for factor Xa-directed anticoagulants.
Circ Res. 2013 Sep 27;113(8):954-7. doi: 10.1161/CIRCRESAHA.113.302297.
Zotero 插件